Canada's Invisible Crisis: The Growing Fight Over Chemical Sensitivity

SAINT-SAUVEUR, QC – April 28, 2026 – An international conference is set to cast a spotlight on a debilitating condition that affects a growing number of Canadians yet remains largely in the shadows of the healthcare system. The Environmental Health Association of Canada (EHAC) and its Quebec counterpart (EHAQ) have announced RESILIENCE 2026, a virtual summit on May 7-8 aimed at confronting the challenges of Multiple Chemical Sensitivity (MCS), a condition that leaves individuals reacting severely to low levels of everyday chemicals.

With over 1.1 million Canadians officially diagnosed, advocates argue that MCS is no longer a niche issue but an emerging public health crisis demanding urgent attention. The conference will bring together researchers, clinicians, and policymakers to move beyond debate and toward tangible solutions for a population struggling for recognition, care, and basic accessibility.

The Invisible Burden

For those with MCS, the world is a minefield. A whiff of perfume, the scent of a cleaning product, or fumes from new paint can trigger a cascade of symptoms ranging from migraines and respiratory distress to cognitive impairment and extreme fatigue. This reality forces many into a state of profound isolation, unable to work, shop for groceries, or even visit a doctor's office without risking a severe reaction.

Data from the Canadian Community Health Survey paints a stark picture of a condition on the rise. Between 2000 and 2020, the prevalence of diagnosed MCS in Canada surged from 1.9% to 3.5% of the population. The condition disproportionately affects women and its prevalence increases with age, signaling a growing challenge for an aging population and the healthcare systems that support it.

Despite its impact, MCS occupies a contentious space in medicine. Lacking a single definitive biomarker, diagnosis relies on symptom patterns and the exclusion of other illnesses, leading many to endure years of medical uncertainty. However, the Canadian Human Rights Commission officially recognizes environmental sensitivities, including MCS, as a disability. This legal recognition mandates accommodation in federally regulated workplaces and services, establishing a right to safe environments. Yet, a significant gap persists between policy and practice, with many individuals fighting arduous battles for scent-free policies and chemically safe housing.

A Public Health Blind Spot

While some critics have historically dismissed MCS as psychosomatic, a growing body of scientific research points toward a physiological basis. Leading experts suggest it is a neurological condition, with studies showing potential abnormalities in brain scans and evidence of sensitization at a cellular level. Dr. John Molot, a prominent Ontario physician who has assessed over 12,000 patients with environmentally linked illnesses, is a key voice in this area. His work, including co-authoring the pivotal 2007 report for the Canadian Human Rights Commission, has been instrumental in framing MCS as a legitimate medical condition requiring serious attention.

Dr. Molot, a featured speaker at the upcoming conference, argues that the science is catching up to the patient experience. His perspective is that the thousands of individuals reporting similar reactions to common chemical exposures cannot be ignored. The challenge, however, is that the Canadian healthcare system has been slow to adapt. Medical schools offer minimal training on environmental health, leaving many physicians unequipped to diagnose or manage MCS. Hospitals and clinics, often filled with scented products and harsh cleaners, can be inaccessible and dangerous for sensitized individuals, creating a cruel paradox where the places designed for healing become sources of harm.

This gap is precisely what RESILIENCE 2026 seeks to address. By positioning MCS as a public health issue, the conference aims to shift the focus toward prevention, improved diagnostic protocols, and the development of competent care models. It underscores the need for public health strategies that consider the impact of ubiquitous chemical exposures on vulnerable populations.

A Convergence for Solutions

The RESILIENCE 2026 conference is structured as a multidisciplinary convergence, reflecting the complex nature of MCS. It is not solely a medical problem but an issue that intersects with human rights, accessibility, and environmental policy. The event is being organized by the EHAC and EHAQ, led by President & CEO Rohini Peris and Executive Director Michel Gaudet, who have long advocated for those affected by environmental health conditions.

The inclusion of speakers like Paul-Claude Bérubé, Executive Director of COPHAN, the confederation of organizations for people with disabilities in Quebec, highlights this broader perspective. His participation ensures that the conversation around MCS is integrated into the larger disability rights movement, emphasizing that accessibility for chemical sensitivities is as critical as physical accessibility.

According to the organizers, the two-day virtual event will provide a platform for international experts to share cutting-edge research, clinical insights, and policy innovations. The goal is to advance practical solutions across systems, from creating safe housing and workplaces to establishing clear clinical pathways for patients. Ahead of the main event, a virtual media briefing on May 6 will offer journalists embargoed information and direct access to these key experts, signaling a concerted effort to foster informed public discourse.

For the more than one million Canadians navigating the daily challenges of MCS, the conference represents a beacon of hope. It signals a potential turning point—a shift from a struggle for individual validation to a collective effort to build a more inclusive and healthier society. By uniting diverse fields of expertise, RESILIENCE 2026 aims to build a foundation for a future where environmental sensitivities are understood, accommodated, and effectively managed within the mainstream of Canadian healthcare and public life.